Highlights
- •Type 2 myocardial infarction patients benefit from prophylactic defibrillator.
- •Type 1 and type 2 MI patients implanted with an ICD have similar outcomes.
- •Appropriate therapies occur even more often in type 2 than in type 1 MI patients.
An implantable cardioverter defibrillator (ICD) is recommended in primary prevention
patients with a coronary artery disease (CAD) and reduced left ventricular ejection
fraction. Benefits of ICD in CAD unrelated to coronary thrombosis are unknown. We
sought to compare the prognosis of patients with CAD implanted with a prophylactic
ICD according to the type of myocardial infarction (MI). Patients from the Very-High-Rate
registry implanted with a prophylactic ICD for CAD between 2006 and 2016 were retrospectively
included. Cardiac resynchronization therapy patients were excluded. Patients with
type 2 MI were matched (1:4) with patients with type 1 MI using propensity score.
The following events were collected: death, hospitalization for heart failure, cardiac
transplantation, and appropriated therapies on ventricular arrhythmia (≥220 beats/min).
Among 571 consecutive ischemic patients, 65 type 2 MI patients were matched to 260
type 1. After a mean follow up of 55 ± 36 months, 63 patients (24%) died in type 1
group, 18 (28%) in type 2 group (p = 0.19). Survival rate from appropriate therapies
on high-rate ventricular arrhythmias was significantly lower in type 2 group (p = 0.04).
In conclusion, patients implanted with a prophylactic ICD for severe CAD, whether
type 1 or type 2 MI, have similar outcomes.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.N Engl J Med. 1996; 335: 1933-1940
- Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure.N Engl J Med. 2005; 352: 225-237
- Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.N Engl J Med. 2002; 346: 877-883
- An extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.Circulation. 2010; 122: 1265-1271
- Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction.N Engl J Med. 2004; 351: 2481-2488
- Defibrillator implantation early after myocardial infarction.N Engl J Med. 2009; 361: 1427-1436
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).Europace. 2015; 17: 1601-1687
- Fourth Universal Definition of Myocardial Infarction.J Am Coll Cardiol. 2018; 72: 2231-2264
- Discrimination of patients with type 2 myocardial infarction.Eur Heart J. 2017; 38: 3514-3520
- Supply/demand type 2 myocardial infarction: should we be paying more attention.J Am Coll Cardiol. 2014; 63: 2079-2087
- Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: results from a large multicenter controlled study.Heart Rhythm. 2017; 14: 211-217
- Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction.Europace. 2012; 14: 968-974
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J. 2018; 39: 119-177
- Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).J Cardiovasc Magn Reson. 2017; 19: 75
- Nonobstructive coronary artery disease and risk of myocardial infarction.JAMA. 2014; 312: 1754-1763
- Coronary microvascular disease in humans.Jpn Heart J. 1999; 40: 97-108
- Coronary microcirculation in ischemic heart disease.Curr Pharm Des. 2018; 24: 2893-2899
- Defibrillator implantation in patients with nonischemic systolic heart failure.N Engl J Med. 2016; 375: 1221-1230
Article info
Publication history
Published online: January 07, 2020
Received in revised form:
December 18,
2019
Received:
October 21,
2019
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
